Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer offers to acquire Japanese OTC firm SSP

This article was originally published in The Tan Sheet

Executive Summary

Boehringer Ingelheim's tender offer for all outstanding shares of its Japanese subsidiary SSP will allow the German pharmaceutical company to "more aggressively" pursue OTC switches, the company says in a Feb. 10 release. The offer to buy the remaining 40 percent of SSP's shares each for 710 yen ($7.89 according to Feb. 10 exchange rates) comes just a few months before Boehringer's patent exclusivity for its prescription benign prostatic hyperplasia drug Flomax (tamsulosin) expires in April. Patent cliffs and generic competition for blockbuster prescriptions drugs are pushing many pharmaceutical firms to diversify their business by developing their consumer health businesses and investing in switch platforms (1"The Tan Sheet" Jan. 4, 2010). After the tender offer, which opens Feb. 15 and closes April 13, Boehringer will merge SSP with another subsidiary - Boehringer Ingelheim Japan Investment; SSP will be the surviving company. The deal gives SSP an avenue to market its products, including cold medicines, vitamins and an OTC insomnia medication, overseas. SSP also will gain access to Boehringer's research and development capabilities

You may also be interested in...



Sanofi Eyes Chattem As Key Building Block For Global OTC Growth

Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS103790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel